Meeting NewsVideo

VIDEO: Ocular Therapeutix updates product pipeline

NEW YORK — From OSN New York 2018, Antony Mattessich, CEO of Ocular Therapeutix, discusses progress toward approval of the dexamethasone implant, Dextenza, as well as other products in the company’s pipeline.

NEW YORK — From OSN New York 2018, Antony Mattessich, CEO of Ocular Therapeutix, discusses progress toward approval of the dexamethasone implant, Dextenza, as well as other products in the company’s pipeline.

    See more from OSN New York Meeting